For Q1 FY2026 (ended March 31, 2026), Odyssey Therapeutics reported zero revenue, a net loss of $38.3 million, and an operating loss of $39.8 million. Diluted EPS was -$6.77. Cash stood at $35.7 million, while stockholders' equity was negative $523.7 million.
•Revenue was $0, down 100% year-over-year.
•Net loss widened to $38.3 million from $26.4 million in the prior year.
•Operating loss increased to $39.8 million from $15.3 million.
•Cash and cash equivalents totaled $35.7 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis.
Its portfolio also includes OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5), OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg, a TSLP/IL-33 bispecific antagonist, an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor, and a small molecule inhibitor of IRF5. Incorporated in 2021, the company is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases. Its pipeline includes several candidates: OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, currently in a Phase 2a trial for ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses and activation of IRF5; OD-003, a protein therapeutic that selectively agonizes tumor necrosis factor receptor 2 on Treg cells; a TSLP/IL-33 bispecific antagonist; an oral small molecule IRAK4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company is headquartered in Boston, Massachusetts, and was incorporated in 2021.
On which stock exchange is Odyssey Therapeutics listed and what is its ticker symbol?
Odyssey Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ODTX. The company trades in U.S. dollars (USD), as it is headquartered in the United States. The NasdaqCM is part of the Nasdaq stock exchange, which is one of the major U.S. exchanges, and it typically lists smaller or emerging growth companies. Investors can buy and sell shares of ODTX during regular trading hours on this exchange.
What sector and industry does Odyssey Therapeutics belong to?
Odyssey Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes, living organisms, or their derivatives to develop products, often for medical applications. As a clinical-stage biopharmaceutical company, Odyssey focuses on discovering and developing novel therapies for autoimmune and inflammatory diseases. This industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight, but also the potential for breakthrough treatments that address unmet medical needs.
Where is Odyssey Therapeutics headquartered and what is its geographic focus?
Odyssey Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. Boston is a major hub for biotechnology and pharmaceutical research, home to numerous academic institutions, hospitals, and biotech companies. While the company is based in the U.S., its pipeline targets autoimmune and inflammatory diseases, which affect patients worldwide. However, based on the available data, the company primarily operates in the United States, as indicated by its country and region being listed as 'United States' and 'us'. The company was incorporated in 2021, making it a relatively young player in the biotech space.
What are the key drug candidates in Odyssey Therapeutics' pipeline?
Odyssey Therapeutics has a diverse pipeline of drug candidates targeting autoimmune and inflammatory diseases. The most advanced is OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2 (RIPK2), currently in a Phase 2a trial for ulcerative colitis. Other candidates include OD-002, an oral SLC15A4 inhibitor that blocks TLR7/8/9-mediated inflammatory responses and IRF5 activation; OD-003, a protein therapeutic that selectively activates TNFR2 on Treg cells; a TSLP/IL-33 bispecific antagonist; an oral small molecule IRAK4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. These candidates address various pathways involved in inflammation and autoimmunity, highlighting the company's focus on innovative mechanisms.